RUNX1 and acute myeloid leukemia: The results, together with previous biochemical, cellular, and in vivo12 assessments, reveal 7.44 as a lead for further optimization of structurally related compounds with increased binding affinity and enhanced anti-leukemic effects to inhibit RUNX1/ETO oncogenic function in t(8;21) AML.